ESSA Pharma Inc (Nasdaq: EPIX), a clinical-stage pharmaceutical company that says it is focused on developing novel therapies for the treatment of prostate cancer, announced on Monday that it has completed an underwritten public offering of 4,830,918 of its common shares.
The shares are priced at USD27 per share before underwriting discounts. The company granted the underwriters a 30-day option to purchase up to an additional 724,637 common shares. The total proceeds from the offering were around USD130m. The joint book-running managers for the offering are Jefferies and Piper Sandler, while lead manager for the offering is Oppenheimer & Co and Bloom Burton Securities Inc acted as co-manager for the offering.
The company aims to use the net proceeds from the offering to fund clinical activities, chemistry, manufacturing and controls, and research and development, working capital and general corporate purposes.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886